Cartesian Therapeutics Q2 net income $15.8M, EPS $0.47; operating loss widens to $29.2M
Cartesian Therapeutics reported second quarter 2026 results with net income of $15.8 million, or $0.47 per basic share, roughly flat with $15.9 million, or $0.51 per share, a year earlier. The result relied on a $49.2 million gain on the contingent value rights liability, while the operating loss widened to $29.2 million from $21.8 million as research and development and general and administrative expenses rose.
Key points
- Q2 2026 net income $15.8 million ($0.47 basic EPS) vs. $15.9 million ($0.51) in Q2 2025.
- Operating loss $29.2 million vs. $21.8 million; R&D expenses $20.4 million vs. $14.9 million.
- Revenue was zero in Q2 2026 vs. $298,000 in Q2 2025.
- Cash, cash equivalents and restricted cash $149.3 million at June 30, 2026, expected to support operations into 2028.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.